Product Portfolio
Our goal is to use our proprietary inhalation technologies to enhance the therapeutic benefits and commercial attractiveness of proven drugs in the field of neurology while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. We have proprietary product candidates in development that address large market opportunities.
Our strategy is to commercialize and develop differentiated neurology product candidates that can address significant unmet medical needs and overcome limitations of existing products. The most advanced product candidate is LEVADEX® (dihydroergotamine mesylate, USP) inhalation aerosol, an orally inhaled investigational migraine drug, for which a New Drug Application (NDA) is currently under review by the U.S. Food and Drug Administration (FDA), with an action date of March 26, 2012 under the Prescription Drug User Fee Act (PDUFA).
Neurology Opportunities
Partnering Opportunities
In addition to our product portfolio, we have partnering opportunities with drug candidates for the treatment of respiratory diseases.
